Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Michiaki Takagi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan. Hauptthemen laut MEDLINE: Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Baricitinib is devel-oped by Eli Lilly and Company.
Abstract (Originalsprache)
Objectives
To assess the safety and effectiveness of baricitinib treatment for rheumatoid arthritis (RA) in real-world clinical practice.
Methods
This ongoing all-case post-marketing surveillance study (starting September 2017) includes all patients with RA treated with baricitinib in Japan. Safety and effectiveness (disease activity) were assessed for 24 weeks.
Results
Safety analyses to February 2021 included 4731 patients (initial baricitinib dose: 4 mg/day, n = 3058; 2 mg/day, n = 1661; other, n = 12); 1059 (22.38%) were ≥75 years and 3362 (71.06%) previously received biologic therapy. The overall observational period was 1863.14 patient-years; 1174 (24.82%) patients discontinued baricitinib before Week 24, mostly for lack of effectiveness (n = 478; 10.10%). Adverse events occurred in 1271 (26.87%) patients [serious: 203 (4.29%); death: 18 (0.38%)]. The incidence of herpes zoster, hepatic function disorder, and serious infection was 3.09%, 2.77%, and 1.90%, respectively. Malignancy occurred in 17 patients (0.36%) and major adverse cardiovascular events in seven patients (0.15%). Among patients with effectiveness data, at least 26.57% (Boolean) achieved remission at Week 24.
Conclusions
This large nationwide surveillance study evaluated the safety and effectiveness of 24 weeks of baricitinib for RA in real-world clinical practice. Continued surveillance of long-term safety is ongoing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan.
- Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
- Matsuno Clinic for Rheumatic Diseases, Toyama, Japan.
- Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan.
- Department of Rheumatology and Clinical Immunology, Wakayama Medical University, Wakayama, Japan.
- Department of Pediatrics, School of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
ORCID-Profile: Michiaki Takagi, Naoto Tamura, Masataka Kuwana
Förderung
- Baricitinib is devel-oped by Eli Lilly and Company
Zitieren
APA
Takagi, M., Atsumi, T., Matsuno, H., Tamura, N., Fujii, T., Okamoto, N., Takahashi, N., Nakajima, A., Nakajima, A., Tsujimoto, N., Nishikawa, A., Ishii, T., Takeuchi, T., & Kuwana, M. (2023). Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. Modern Rheumatology. https://doi.org/10.1093/mr/roac089
Vancouver
Takagi M, Atsumi T, Matsuno H, Tamura N, Fujii T, Okamoto N, et al. Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. Modern Rheumatology. 2023. doi:10.1093/mr/roac089
BibTeX
@article{Takagi2023,
author = {Takagi, Michiaki and Atsumi, Tatsuya and Matsuno, Hiroaki and Tamura, Naoto and Fujii, Takao and Okamoto, Nami and Takahashi, Nobunori and Nakajima, Atsuo and Nakajima, Ayako and Tsujimoto, Naoto and Nishikawa, Atsushi and Ishii, Taeko and Takeuchi, Tsutomu and Kuwana, Masataka},
title = {Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac089}
}
EUVIMED